{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T22:10:00Z","timestamp":1789596600383,"version":"build-2803163510"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"DOI":"10.1186\/s12935-025-03702-4","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T16:03:45Z","timestamp":1742400225000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Advancing the therapeutic effectiveness of paclitaxel in chronic lymphocytic leukemia through the simultaneous inhibition of NOTCH1 and SF3B1"],"prefix":"10.1186","volume":"25","author":[{"given":"Shiva","family":"Abolhasani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin Mahmoud","family":"salehi Khesht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atefeh","family":"Khodakarami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Masjedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bentolhoda","family":"Rashidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sepideh","family":"Izadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh Karimian","family":"Noukabadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vahid","family":"Karpisheh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khatereh Torabi","family":"Poudeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooya","family":"Jalali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Salehi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafieh","family":"Bagherifar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyyed Sina","family":"Hejazian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AliAkbar","family":"Movassaghpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbas Ali Hosseinpour","family":"Feizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Jadidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,19]]},"reference":[{"issue":"5","key":"3702_CR1","doi-asserted-by":"publisher","first-page":"853","DOI":"10.3390\/diagnostics11050853","volume":"11","author":"C Perez-Carretero","year":"2021","unstructured":"Perez-Carretero C, Gonzalez-Gascon YMI, Rodriguez-Vicente AE, Quijada-Alamo M, Hernandez-Rivas JA, Hernandez-Sanchez M, Hernandez-Rivas JM. The evolving landscape of chronic lymphocytic leukemia on diagnosis, prognosis and treatment. Diagnostics (Basel). 2021;11(5):853.","journal-title":"Diagnostics (Basel)"},{"key":"3702_CR2","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-C\u00e1novas JL, del Rio-Moreno M, Garc\u00eda-Fernandez H, Jim\u00e9nez-Vacas JM, Moreno-Montilla MT, S\u00e1nchez-Frias ME, Amado V, Fernando L, Fondevila MF, Ciria RJCL. Splicing factor SF3B1 is overexpressed and implicated in the aggressiveness and survival of hepatocellular carcinoma. 2021, 496:72\u201383.","DOI":"10.1016\/j.canlet.2020.10.010"},{"key":"3702_CR3","doi-asserted-by":"crossref","unstructured":"Zhang L, Zhang X, Zhang H, Liu F, Bi Y, Zhang Y, Cheng C, Liu JJBC. Knockdown of SF3B1 inhibits cell proliferation, invasion and migration triggering apoptosis in breast cancer via aberrant splicing. 2020, 27:464\u201376.","DOI":"10.1007\/s12282-020-01045-8"},{"key":"3702_CR4","doi-asserted-by":"crossref","unstructured":"Kunnimalaiyaan M, Vaccaro AM, Ndiaye MA, Chen HJJC. Overexpression of the NOTCH1 intracellular domain inhibits cell proliferation and alters the neuroendocrine phenotype of medullary thyroid cancer cells. 2006, 281(52):39819\u201330.","DOI":"10.1074\/jbc.M603578200"},{"key":"3702_CR5","doi-asserted-by":"crossref","unstructured":"Yin S, Gambe RG, Sun J, Martinez AZ, Cartun ZJ, Regis FFD, Wan Y, Fan J, Brooks AN, Herman SEJCC. A murine model of chronic lymphocytic leukemia based on B cell-restricted expression of Sf3b1 mutation and atm deletion. 2019, 35(2):283\u201396. e285.","DOI":"10.1016\/j.ccell.2018.12.013"},{"key":"3702_CR6","doi-asserted-by":"crossref","unstructured":"Di Ianni M, Baldoni S, Del Papa B, Aureli P, Dorillo E, De Falco F, Albi E, Varasano E, Di Tommaso A. Giancola RJFio: NOTCH1 is aberrantly activated in chronic lymphocytic leukemia hematopoietic stem cells. 2018;8:105.","DOI":"10.3389\/fonc.2018.00105"},{"issue":"1","key":"3702_CR7","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/leu.2013.263","volume":"28","author":"S Jeromin","year":"2014","unstructured":"Jeromin S, Weissmann S, Haferlach C, Dicker F, Bayer K, Grossmann V, Alpermann T, Roller A, Kohlmann A, Haferlach T, et al. SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients. Leukemia. 2014;28(1):108\u201317.","journal-title":"Leukemia"},{"issue":"26","key":"3702_CR8","doi-asserted-by":"publisher","first-page":"6904","DOI":"10.1182\/blood-2011-08-373159","volume":"118","author":"D Rossi","year":"2011","unstructured":"Rossi D, Bruscaggin A, Spina V, Rasi S, Khiabanian H, Messina M, Fangazio M, Vaisitti T, Monti S, Chiaretti S, et al. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. Blood. 2011;118(26):6904\u20138.","journal-title":"Blood"},{"issue":"26","key":"3702_CR9","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1056\/NEJMoa1109016","volume":"365","author":"L Wang","year":"2011","unstructured":"Wang L, Lawrence MS, Wan Y, Stojanov P, Sougnez C, Stevenson K, Werner L, Sivachenko A, DeLuca DS, Zhang L. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med. 2011;365(26):2497\u2013506.","journal-title":"N Engl J Med"},{"issue":"1","key":"3702_CR10","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/ng.1032","volume":"44","author":"V Quesada","year":"2011","unstructured":"Quesada V, Conde L, Villamor N, Ordonez GR, Jares P, Bassaganyas L, Ramsay AJ, Bea S, Pinyol M, Martinez-Trillos A, et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet. 2011;44(1):47\u201352.","journal-title":"Nat Genet"},{"issue":"5","key":"3702_CR11","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.ccell.2016.10.005","volume":"30","author":"L Wang","year":"2016","unstructured":"Wang L, Brooks AN, Fan J, Wan Y, Gambe R, Li S, Hergert S, Yin S, Freeman SS, Levin JZ, et al. Transcriptomic characterization of SF3B1 mutation reveals its pleiotropic effects in chronic lymphocytic leukemia. Cancer Cell. 2016;30(5):750\u201363.","journal-title":"Cancer Cell"},{"issue":"2","key":"3702_CR12","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ccell.2018.12.013","volume":"35","author":"S Yin","year":"2019","unstructured":"Yin S, Gambe RG, Sun J, Martinez AZ, Cartun ZJ, Regis FFD, Wan Y, Fan J, Brooks AN, Herman SEM, et al. A murine model of chronic lymphocytic leukemia based on B Cell-Restricted expression of Sf3b1 mutation and atm deletion. Cancer Cell. 2019;35(2):283\u201396. e285.","journal-title":"Cancer Cell"},{"issue":"6","key":"3702_CR13","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1111\/j.1365-2141.2009.07816.x","volume":"146","author":"M Di Ianni","year":"2009","unstructured":"Di Ianni M, Baldoni S, Rosati E, Ciurnelli R, Cavalli L, Martelli MF, Marconi P, Screpanti I, Falzetti F. A new genetic lesion in B-CLL: a NOTCH1 PEST domain mutation. Br J Haematol. 2009;146(6):689\u201391.","journal-title":"Br J Haematol"},{"issue":"4","key":"3702_CR14","doi-asserted-by":"publisher","first-page":"e135","DOI":"10.3324\/haematol.2015.136051","volume":"101","author":"S Rasi","year":"2016","unstructured":"Rasi S, Khiabanian H, Ciardullo C, Terzi-di-Bergamo L, Monti S, Spina V, Bruscaggin A, Cerri M, Deambrogi C, Martuscelli L, et al. Clinical impact of small subclones harboring NOTCH1, SF3B1 or BIRC3 mutations in chronic lymphocytic leukemia. Haematologica. 2016;101(4):e135\u2013138.","journal-title":"Haematologica"},{"issue":"7","key":"3702_CR15","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1084\/jem.20110921","volume":"208","author":"G Fabbri","year":"2011","unstructured":"Fabbri G, Rasi S, Rossi D, Trifonov V, Khiabanian H, Ma J, Grunn A, Fangazio M, Capello D, Monti S, et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med. 2011;208(7):1389\u2013401.","journal-title":"J Exp Med"},{"issue":"14","key":"3702_CR16","doi-asserted-by":"publisher","first-page":"E2911","DOI":"10.1073\/pnas.1702564114","volume":"114","author":"G Fabbri","year":"2017","unstructured":"Fabbri G, Holmes AB, Viganotti M, Scuoppo C, Belver L, Herranz D, Yan XJ, Kieso Y, Rossi D, Gaidano G, et al. Common nonmutational NOTCH1 activation in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2017;114(14):E2911\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"3702_CR17","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/leu.2015.182","volume":"30","author":"F Pozzo","year":"2016","unstructured":"Pozzo F, Bittolo T, Arruga F, Bulian P, Macor P, Tissino E, Gizdic B, Rossi FM, Bomben R, Zucchetto A, et al. NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dysregulation. Leukemia. 2016;30(1):182\u20139.","journal-title":"Leukemia"},{"issue":"1","key":"3702_CR18","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/leu.2014.143","volume":"29","author":"M L\u00f3pez-Guerra","year":"2015","unstructured":"L\u00f3pez-Guerra M, Xargay-Torrent S, Rosich L, Montraveta A, Rold\u00e1n J, Matas-C\u00e9spedes A, Villamor N, Aymerich M, L\u00f3pez-Ot\u00edn C, P\u00e9rez-Gal\u00e1n P, et al. The \u03b3-secretase inhibitor PF-03084014 combined with fludarabine antagonizes migration, invasion and angiogenesis in NOTCH1-mutated CLL cells. Leukemia. 2015;29(1):96\u2013106.","journal-title":"Leukemia"},{"issue":"2","key":"3702_CR19","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/leu.2015.286","volume":"30","author":"M Larrayoz","year":"2016","unstructured":"Larrayoz M, Blakemore SJ, Dobson RC, Blunt MD, Rose-Zerilli MJ, Walewska R, Duncombe A, Oscier D, Koide K, Forconi F, et al. The SF3B1 inhibitor spliceostatin A (SSA) elicits apoptosis in chronic lymphocytic leukaemia cells through downregulation of Mcl-1. Leukemia. 2016;30(2):351\u201360.","journal-title":"Leukemia"},{"key":"3702_CR20","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.colsurfb.2016.08.022","volume":"149","author":"Y Wang","year":"2017","unstructured":"Wang Y, Zhou L, Xiao M, Sun Z-L, Zhang C-Y. Nanomedicine-based Paclitaxel induced apoptotic signaling pathways in A562 leukemia cancer cells. Colloids Surf B. 2017;149:16\u201322.","journal-title":"Colloids Surf B"},{"issue":"11","key":"3702_CR21","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1038\/sj.bmt.1703293","volume":"28","author":"Y Nieto","year":"2001","unstructured":"Nieto Y, Bearman SI, Shpall EJ, Jones RB, Cagnoni PJ, Rabinovitch RA, McSweeney PA. Intensive chemotherapy for progressive chronic lymphocytic leukemia administered early after a nonmyeloablative allograft. Bone Marrow Transplant. 2001;28(11):1083\u20136.","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"3702_CR22","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1002\/pbc.21310","volume":"50","author":"TM Horton","year":"2008","unstructured":"Horton TM, Ames MM, Reid JM, Krailo MD, Pendergrass T, Mosher R, Reaman GH, Seibel NL. A phase 1 and Pharmacokinetic clinical trial of Paclitaxel for the treatment of refractory leukemia in children: a children\u2019s oncology group study. Pediatr Blood Cancer. 2008;50(4):788\u201392.","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"3702_CR23","doi-asserted-by":"publisher","first-page":"15013904","DOI":"10.4238\/gmr.15013904","volume":"15","author":"ZG Peng","year":"2016","unstructured":"Peng ZG, Liu DC, Yao YB, Feng XL, Huang X, Tang YL, Yang J, Wang XX. Paclitaxel induces apoptosis in leukemia cells through a JNK activation-dependent pathway. Genet Mol Research: GMR. 2016;15(1):15013904.","journal-title":"Genet Mol Research: GMR"},{"key":"3702_CR24","doi-asserted-by":"publisher","first-page":"119576","DOI":"10.1016\/j.ijpharm.2020.119576","volume":"586","author":"Z Li","year":"2020","unstructured":"Li Z, Zhang Y, Zhu C, Guo T, Xia Q, Hou X, Liu W, Feng N. Folic acid modified lipid-bilayer coated mesoporous silica nanoparticles co-loading Paclitaxel and Tanshinone IIA for the treatment of acute promyelocytic leukemia. Int J Pharm. 2020;586:119576.","journal-title":"Int J Pharm"},{"issue":"1\u20132","key":"3702_CR25","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.ijpharm.2017.05.016","volume":"526","author":"E Bernabeu","year":"2017","unstructured":"Bernabeu E, Cagel M, Lagomarsino E, Moretton M, Chiappetta DA. Paclitaxel: what has been done and the challenges remain ahead. Int J Pharm. 2017;526(1\u20132):474\u201395.","journal-title":"Int J Pharm"},{"issue":"1","key":"3702_CR26","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.canlet.2015.07.008","volume":"367","author":"L Tong","year":"2015","unstructured":"Tong L, Chuang C-C, Wu S, Zuo L. Reactive oxygen species in redox cancer therapy. Cancer Lett. 2015;367(1):18\u201325.","journal-title":"Cancer Lett"},{"issue":"1","key":"3702_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/1568009033333754","volume":"3","author":"R Yusuf","year":"2003","unstructured":"Yusuf R, Duan Z, Lamendola D, Penson R, Seiden M. Paclitaxel resistance: molecular mechanisms and Pharmacologic manipulation. Curr Cancer Drug Targets. 2003;3(1):1\u201319.","journal-title":"Curr Cancer Drug Targets"},{"issue":"1","key":"3702_CR28","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1080\/10717544.2017.1378938","volume":"24","author":"F Xie","year":"2017","unstructured":"Xie F, Ding RL, He WF, Liu ZJ, Fu SZ, Wu JB, Yang LL, Lin S, Wen QL. In vivo antitumor effect of endostatin-loaded Chitosan nanoparticles combined with Paclitaxel on Lewis lung carcinoma. Drug Deliv. 2017;24(1):1410\u20138.","journal-title":"Drug Deliv"},{"issue":"2","key":"3702_CR29","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1080\/10717544.2017.1399305","volume":"24","author":"G Huang","year":"2017","unstructured":"Huang G, Liu Y, Chen L. Chitosan and its derivatives as vehicles for drug delivery. Drug Delivery. 2017;24(2):108\u201313.","journal-title":"Drug Delivery"},{"key":"3702_CR30","doi-asserted-by":"publisher","first-page":"119369","DOI":"10.1016\/j.lfs.2021.119369","volume":"275","author":"N Joshi","year":"2021","unstructured":"Joshi N, Hajizadeh F, Dezfouli EA, Zekiy AO, Afjadi MN, Mousavi SM, Hojjat-Farsangi M, Karpisheh V, Mahmoodpoor A, Hassannia H. Silencing STAT3 enhances sensitivity of cancer cells to doxorubicin and inhibits tumor progression. Life Sci. 2021;275:119369.","journal-title":"Life Sci"},{"key":"3702_CR31","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jconrel.2016.12.012","volume":"246","author":"F Jadidi-Niaragh","year":"2017","unstructured":"Jadidi-Niaragh F, Atyabi F, Rastegari A, Kheshtchin N, Arab S, Hassannia H, Ajami M, Mirsanei Z, Habibi S, Masoumi F. CD73 specific SiRNA loaded Chitosan lactate nanoparticles potentiate the antitumor effect of a dendritic cell vaccine in 4T1 breast cancer bearing mice. J Controlled Release. 2017;246:46\u201359.","journal-title":"J Controlled Release"},{"key":"3702_CR32","doi-asserted-by":"crossref","unstructured":"Khodakarami A, Kashani MA, Nazer A, Kheshti AM, Rashidi B, Karpisheh V, Masjedi A, Abolhasani S, Izadi S, Bagherifar RJCC et al. Targeted Silencing of NRF2 by rituximab-conjugated nanoparticles increases the sensitivity of chronic lymphoblastic leukemia cells to cyclophosphamide. 2023, 21(1):188.","DOI":"10.1186\/s12964-023-01213-1"},{"key":"3702_CR33","first-page":"2989","volume":"130","author":"J Dos Santos","year":"2017","unstructured":"Dos Santos J, Enfield L, Dos Santos SB, Allenby MC, Zemenides S, Mantalaris A, Panoskaltsis N. Primary chronic lymphocytic leukemia cells can be maintained long-term in serum-free, cytokine-free 3D culture. Blood. 2017;130:2989.","journal-title":"Blood"},{"key":"3702_CR34","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.leukres.2015.10.008","volume":"40","author":"J Kellner","year":"2016","unstructured":"Kellner J, Wierda W, Shpall E, Keating M, McNiece I. Isolation of a novel chronic lymphocytic leukemic (CLL) cell line and development of an in vivo mouse model of CLL. Leuk Res. 2016;40:54\u20139.","journal-title":"Leuk Res"},{"key":"3702_CR35","doi-asserted-by":"publisher","first-page":"639572","DOI":"10.3389\/fimmu.2021.639572","volume":"12","author":"FV Sbrana","year":"2021","unstructured":"Sbrana FV, Pinos R, Barbaglio F, Scagnoli F, Scarf\u00f2 L, Redwan IN, Far\u00e8 S, Ghia P, Scielzo C. 3D Bioprinting allows the establishment of long-term 3D culture model for chronic lymphocytic leukemia cells. Front Immunol. 2021;12:639572.","journal-title":"Front Immunol"},{"key":"3702_CR36","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.ijbiomac.2019.03.223","volume":"133","author":"A Masjedi","year":"2019","unstructured":"Masjedi A, Hassannia H, Atyabi F, Rastegari A, Hojjat-Farsangi M, Namdar A, Soleimanpour H, Azizi G, Nikkhoo A, Ghalamfarsa G. Downregulation of A2AR by SiRNA loaded PEG-chitosan-lactate nanoparticles restores the T cell mediated anti-tumor responses through blockage of PKA\/CREB signaling pathway. Int J Biol Macromol. 2019;133:436\u201345.","journal-title":"Int J Biol Macromol"},{"key":"3702_CR37","doi-asserted-by":"crossref","unstructured":"Adibfar S, Masjedi A, Nazer A, Rashidi B, Karpisheh V, Izadi S, Hassannia H, Navashenaq JG, Mohammadi H. Hojjat-Farsangi MJLs: combined Inhibition of EZH2 and CD73 molecules by folic acid-conjugated SPION-TMC nanocarriers loaded with SiRNA molecules prevents TNBC progression and restores anti-tumor responses. 2022, 309:121008.","DOI":"10.1016\/j.lfs.2022.121008"},{"issue":"2","key":"3702_CR38","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.colsurfb.2006.04.009","volume":"50","author":"F-Q Hu","year":"2006","unstructured":"Hu F-Q, Ren G-F, Yuan H, Du Y-Z, Zeng S. Shell cross-linked stearic acid grafted Chitosan oligosaccharide self-aggregated micelles for controlled release of Paclitaxel. Colloids Surf B. 2006;50(2):97\u2013103.","journal-title":"Colloids Surf B"},{"key":"3702_CR39","doi-asserted-by":"publisher","first-page":"145","DOI":"10.22159\/ajpcr.2016.v9s3.12894","volume":"9","author":"T SARKAR","year":"2016","unstructured":"SARKAR T, AHMED AB. Development and in-vitro characterisation of Chitosan loaded Paclitaxel nanoparticle. Asian J Pharm Clin Res. 2016;9:145\u20138.","journal-title":"Asian J Pharm Clin Res"},{"key":"3702_CR40","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.ijbiomac.2021.07.034","volume":"186","author":"AMS Khesht","year":"2021","unstructured":"Khesht AMS, Karpisheh V, Gilan PS, Melnikova LA, Zekiy AO, Mohammadi M, Hojjat-Farsangi M, Zolbanin NM, Mahmoodpoor A, Hassannia H. Blockade of CD73 using SiRNA loaded Chitosan lactate nanoparticles functionalized with TAT-hyaluronate enhances doxorubicin mediated cytotoxicity in cancer cells both in vitro and in vivo. Int J Biol Macromol. 2021;186:849\u201363.","journal-title":"Int J Biol Macromol"},{"key":"3702_CR41","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.jep.2015.04.015","volume":"169","author":"M Yongping","year":"2015","unstructured":"Yongping M, Zhang X, Xuewei L, Fan W, Chen J, Zhang H, Chen G, Liu C, Liu P. Astragaloside prevents BDL-induced liver fibrosis through Inhibition of Notch signaling activation. J Ethnopharmacol. 2015;169:200\u20139.","journal-title":"J Ethnopharmacol"},{"key":"3702_CR42","first-page":"e919460","volume":"26","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Yuan Z, Jiang Y, Shen R, Gu M, Xu W, Gu X. Inhibition of splicing factor 3b subunit 1 (SF3B1) reduced cell proliferation, induced apoptosis and resulted in cell cycle arrest by regulating homeobox A10 (HOXA10) splicing in AGS and MKN28 human gastric cancer cells. Med Sci Monitor: Int Med J Experimental Clin Res. 2020;26:e919460\u2013919461.","journal-title":"Med Sci Monitor: Int Med J Experimental Clin Res"},{"key":"3702_CR43","doi-asserted-by":"publisher","first-page":"103868","DOI":"10.1016\/j.jddst.2022.103868","volume":"77","author":"AAH Feizi","year":"2022","unstructured":"Feizi AAH, Vakili-Samiani S, Karpisheh V, Masjedi A, Izadi S, Adibfar S, Nikkhoo A, Hojjat-Farsangi M, Atyabi F, Movassaghpour AA. Increased susceptibility to doxorubicin-induced cell death in acute lymphocytic leukemia cells by inhibiting serine\/threonine WEE1 kinase expression using the chitosan-carboxymethyl dextran-polyethylene glycol-TAT nanoparticles. J Drug Deliv Sci Technol. 2022;77:103868.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"D1","key":"3702_CR44","doi-asserted-by":"publisher","first-page":"D127","DOI":"10.1093\/nar\/gkz757","volume":"48","author":"Y Chen","year":"2020","unstructured":"Chen Y, Wang X. MiRDB: an online database for prediction of functional MicroRNA targets. Nucleic Acids Res. 2020;48(D1):D127\u201331.","journal-title":"Nucleic Acids Res"},{"issue":"W1","key":"3702_CR45","doi-asserted-by":"publisher","first-page":"W244","DOI":"10.1093\/nar\/gkaa467","volume":"48","author":"L Chang","year":"2020","unstructured":"Chang L, Zhou G, Soufan O, Xia J. MiRNet 2.0: network-based visual analytics for MiRNA functional analysis and systems biology. Nucleic Acids Res. 2020;48(W1):W244\u201351.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"3702_CR46","doi-asserted-by":"publisher","first-page":"btac812","DOI":"10.1093\/bioinformatics\/btac812","volume":"39","author":"Z Li","year":"2023","unstructured":"Li Z, Zhang Y, Fang J, Xu Z, Zhang H, Mao M, Chen Y, Zhang L, Pian C. NcPath: A novel platform for visualization and enrichment analysis of human non-coding RNA and KEGG signaling pathways. Bioinformatics. 2023;39(1):btac812.","journal-title":"Bioinformatics"},{"issue":"11","key":"3702_CR47","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1038\/s41571-019-0239-8","volume":"16","author":"F Bosch","year":"2019","unstructured":"Bosch F, Dalla-Favera R. Chronic lymphocytic leukaemia: from genetics to treatment. Nat Reviews Clin Oncol. 2019;16(11):684\u2013701.","journal-title":"Nat Reviews Clin Oncol"},{"issue":"18","key":"3702_CR48","doi-asserted-by":"publisher","first-page":"16559","DOI":"10.18632\/oncotarget.4116","volume":"6","author":"F De Falco","year":"2015","unstructured":"De Falco F, Sabatini R, Del Papa B, Falzetti F, Di Ianni M, Sportoletti P, Baldoni S, Screpanti I, Marconi P, Rosati E. Notch signaling sustains the expression of Mcl-1 and the activity of eIF4E to promote cell survival in CLL. Oncotarget. 2015;6(18):16559\u201372.","journal-title":"Oncotarget"},{"issue":"4","key":"3702_CR49","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1074\/mcp.RA117.000539","volume":"17","author":"HE Johnston","year":"2018","unstructured":"Johnston HE, Carter MJ, Larrayoz M, Clarke J, Garbis SD, Oscier D, Strefford JC, Steele AJ, Walewska R, Cragg MS. Proteomics profiling of CLL versus healthy B-cells identifies putative therapeutic targets and a Subtype-independent signature of spliceosome dysregulation. Mol Cell Proteom. 2018;17(4):776\u201391.","journal-title":"Mol Cell Proteom"},{"issue":"5","key":"3702_CR50","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.celrep.2015.09.053","volume":"13","author":"B Darman Rachel","year":"2015","unstructured":"Darman Rachel B, Seiler M, Agrawal Anant A, Lim Kian H, Peng S, Aird D, Bailey Suzanna L, Bhavsar Erica B, Chan B, Colla S, et al. Cancer-Associated SF3B1 hotspot mutations induce cryptic 3\u2032 splice site selection through use of a different branch point. Cell Rep. 2015;13(5):1033\u201345.","journal-title":"Cell Rep"},{"issue":"7","key":"3702_CR51","doi-asserted-by":"publisher","first-page":"945","DOI":"10.3324\/haematol.2014.122069","volume":"100","author":"MK Kashyap","year":"2015","unstructured":"Kashyap MK, Kumar D, Villa R, La Clair JJ, Benner C, Sasik R, Jones H, Ghia EM, Rassenti LZ, Kipps TJ, et al. Targeting the spliceosome in chronic lymphocytic leukemia with the macrolides FD-895 and pladienolide-B. Haematologica. 2015;100(7):945\u201354.","journal-title":"Haematologica"},{"issue":"26","key":"3702_CR52","doi-asserted-by":"publisher","first-page":"22734","DOI":"10.18632\/oncotarget.4212","volume":"6","author":"S Xargay-Torrent","year":"2015","unstructured":"Xargay-Torrent S, L\u00f3pez-Guerra M, Rosich L, Montraveta A, Rold\u00e1n J, Rodr\u00edguez V, Villamor N, Aymerich M, Lagisetti C, Webb TR. The splicing modulator Sudemycin induces a specific antitumor response and cooperates with ibrutinib in chronic lymphocytic leukemia. Oncotarget. 2015;6(26):22734.","journal-title":"Oncotarget"},{"issue":"D1","key":"3702_CR53","doi-asserted-by":"publisher","first-page":"D605","DOI":"10.1093\/nar\/gkaa1074","volume":"49","author":"D Szklarczyk","year":"2021","unstructured":"Szklarczyk D, Gable AL, Nastou KC, Lyon D, Kirsch R, Pyysalo S, Doncheva NT, Legeay M, Fang T, Bork P. The STRING database in 2021: customizable protein\u2013protein networks, and functional characterization of user-uploaded gene\/measurement sets. Nucleic Acids Res. 2021;49(D1):D605\u201312.","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"3702_CR54","doi-asserted-by":"publisher","first-page":"8403","DOI":"10.1007\/s13277-015-4732-0","volume":"37","author":"F Jadidi-Niaragh","year":"2016","unstructured":"Jadidi-Niaragh F, Atyabi F, Rastegari A, Mollarazi E, Kiani M, Razavi A, Yousefi M, Kheshtchin N, Hassannia H, Hadjati J. Downregulation of CD73 in 4T1 breast cancer cells through siRNA-loaded chitosan-lactate nanoparticles. Tumor Biology. 2016;37(6):8403\u201312.","journal-title":"Tumor Biology"},{"issue":"2","key":"3702_CR55","doi-asserted-by":"publisher","first-page":"181","DOI":"10.2147\/nano.2006.1.2.181","volume":"1","author":"N Bhattarai","year":"2006","unstructured":"Bhattarai N, Ramay HR, Chou S-H, Zhang M. Chitosan and lactic acid-grafted Chitosan nanoparticles as carriers for prolonged drug delivery. Int J Nanomed. 2006;1(2):181.","journal-title":"Int J Nanomed"},{"issue":"1","key":"3702_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11051-014-2821-4","volume":"17","author":"P Soni","year":"2015","unstructured":"Soni P, Kaur J, Tikoo K. Dual drug-loaded paclitaxel\u2013thymoquinone nanoparticles for effective breast cancer therapy. J Nanopart Res. 2015;17(1):1\u201312.","journal-title":"J Nanopart Res"},{"issue":"7","key":"3702_CR57","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s11095-020-02819-7","volume":"37","author":"CD Phung","year":"2020","unstructured":"Phung CD, Le TG, Nguyen VH, Vu TT, Nguyen HQ, Kim JO, Yong CS, Nguyen CN. PEGylated-Paclitaxel and Dihydroartemisinin nanoparticles for simultaneously delivering Paclitaxel and Dihydroartemisinin to colorectal Cancer. Pharm Res. 2020;37(7):129.","journal-title":"Pharm Res"},{"issue":"9","key":"3702_CR58","doi-asserted-by":"publisher","first-page":"e350","DOI":"10.1038\/bcj.2015.80","volume":"5","author":"C Papayannidis","year":"2015","unstructured":"Papayannidis C, DeAngelo D, Stock W, Huang B, Shaik M, Cesari R, Zheng X, Reynolds J, English P, Ozeck M. A phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Blood cancer J. 2015;5(9):e350\u2013350.","journal-title":"Blood cancer J"},{"issue":"6","key":"3702_CR59","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1038\/s41388-019-1053-6","volume":"39","author":"M L\u00f3pez-Guerra","year":"2020","unstructured":"L\u00f3pez-Guerra M, Xargay-Torrent S, Fuentes P, Rold\u00e1n J, Gonz\u00e1lez-Farr\u00e9 B, Rosich L, Silkenstedt E, Garc\u00eda-Le\u00f3n MJ, Lee-Verg\u00e9s E, Gim\u00e9nez N, et al. Specific NOTCH1 antibody targets DLL4-induced proliferation, migration, and angiogenesis in NOTCH1-mutated CLL cells. Oncogene. 2020;39(6):1185\u201397.","journal-title":"Oncogene"},{"issue":"2","key":"3702_CR60","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/leu.2013.183","volume":"28","author":"V Agnusdei","year":"2014","unstructured":"Agnusdei V, Minuzzo S, Frasson C, Grassi A, Axelrod F, Satyal S, Gurney A, Hoey T, Seganfreddo E, Basso G, et al. Therapeutic antibody targeting of Notch1 in T-acute lymphoblastic leukemia xenografts. Leukemia. 2014;28(2):278\u201388.","journal-title":"Leukemia"},{"issue":"1","key":"3702_CR61","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1186\/s13046-019-1458-7","volume":"38","author":"E Silkenstedt","year":"2019","unstructured":"Silkenstedt E, Arenas F, Colom-Sanmart\u00ed B, Xargay-Torrent S, Higashi M, Gir\u00f3 A, Rodriguez V, Fuentes P, Aulitzky WE, van der Kuip H, et al. Notch1 signaling in NOTCH1-mutated mantle cell lymphoma depends on Delta-Like ligand 4 and is a potential target for specific antibody therapy. J Experimental Clin Cancer Res. 2019;38(1):446.","journal-title":"J Experimental Clin Cancer Res"},{"key":"3702_CR62","doi-asserted-by":"crossref","unstructured":"G\u0119barowska K, Mroczek A, Kowalczyk JR, Lejman M. MicroRNA as a prognostic and diagnostic marker in T-Cell acute lymphoblastic leukemia. Int J Mol Sci 2021, 22(10).","DOI":"10.3390\/ijms22105317"},{"issue":"6","key":"3702_CR63","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.blre.2018.04.003","volume":"32","author":"M Drobna","year":"2018","unstructured":"Drobna M, Szarzy\u0144ska-Zawadzka B, Dawidowska M. T-cell acute lymphoblastic leukemia from MiRNA perspective: basic concepts, experimental approaches, and potential biomarkers. Blood Rev. 2018;32(6):457\u201372.","journal-title":"Blood Rev"},{"issue":"3","key":"3702_CR64","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.neo.2019.01.004","volume":"21","author":"M Dawidowska","year":"2019","unstructured":"Dawidowska M, Jaksik R, Drobna M, Szarzy\u0144ska-Zawadzka B, Kosmalska M, S\u0119dek \u0141, Machowska L, Lalik A, Lejman M, Ussowicz M. Comprehensive investigation of mirnome identifies novel candidate miRNA-mRNA interactions implicated in T-cell acute lymphoblastic leukemia. Neoplasia. 2019;21(3):294\u2013310.","journal-title":"Neoplasia"},{"issue":"10","key":"3702_CR65","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1016\/j.clml.2019.09.095","volume":"19","author":"J Chim","year":"2019","unstructured":"Chim J, Li Z. Epigenetic Silencing of miR-340-5p in multiple myeloma: mechanisms and prognostic impact. Clin Lymphoma Myeloma Leuk. 2019;19(10):e61.","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-025-03702-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-025-03702-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-025-03702-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T21:48:24Z","timestamp":1742420904000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerci.biomedcentral.com\/articles\/10.1186\/s12935-025-03702-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,19]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3702"],"URL":"https:\/\/doi.org\/10.1186\/s12935-025-03702-4","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,19]]},"assertion":[{"value":"9 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Peripheral blood and bone marrow specimens were acquired from 11 untreated CLL cases following written informed consent based on the Declaration of Helsinki and approval from the ethical committee of Tabriz University of Medical Sciences (ethic code: IR.TBZMED.REC.1399.960).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"104"}}